Hurting for revenue, Mylan shells out $130M for basket of Aspen drugs

With share prices tumbling and a massive drug-price fixing lawsuit hanging over its head, Mylan’s future is looking increasingly spooky. Could a modest acquisition help turn the tide?

It's willing to try and find out. The Pennsylvania drugmaker will shell out $130 million for Aspen Pharmacare’s portfolio of prescription and over-the-counter products in Australia and New Zealand as part of a distribution deal the companies signed in December.